What is a benefit of use of risperidone and olanzapine for individuals with Alzheimer's disease?

A. While olanzapine in particular is associated with weight gain and increased appetite, this is considered a side effect, not a therapeutic benefit in Alzheimer’s disease. Appetite stimulation is not the primary reason these medications are prescribed. B. Amplifying the effects of other drugs is not a therapeutic benefit and may actually increase the risk of adverse effects or drug interactions. This would be considered a safety concern rather than an advantage. C. Risperidone and olanzapine are atypical antipsychotics and do not improve memory or cognitive decline associated with Alzheimer’s disease. Cognitive symptoms are more appropriately targeted with cholinesterase inhibitors (e.g., donepezil) or memantine. D. Risperidone and olanzapine can help decrease neuropsychiatric symptoms associated with Alzheimer’s disease, such as agitation, aggression, hallucinations, and severe behavioral disturbances. These symptoms are often referred to as Behavioral and Psychological Symptoms of Dementia (BPSD). When nonpharmacologic interventions are ineffective and behaviors pose a safety risk, atypical antipsychotics may be used cautiously.